Fludarabine, treosulfan and etoposide sensitivity and the outcome of hematopoietic stem cell transplantation in childhood acute myeloid leukemia

Anticancer Research

Volumn 27, Issue 3 B, 2007, Pages 1547-1551

  Styczynski, Jan ^a,j   Toporski, Jacek ^b   Wysocki, Mariusz ^a   Debski, Robert ^a   Chybicka, Alicja ^b   Boruczkowski, Dariusz ^c   Wachowiak, Jacek ^c   Wojcik, Beata ^d   Kowalczyk, Jerzy ^d   Gil, Lidia ^c   Balwierz, Walentyna ^e   Matysiak, Michal ^f   Krawczuk Rybak, Maryna ^g   Balcerska, Anna ^h   Sonta Jakimczyk, Danuta ⁱ  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^d MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^e JAGIELLONIAN UNIVERSITY   (Poland)

^f MEDICAL UNIVERSITY OF WARSAW   (Poland)

^g MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^h MEDICAL UNIVERSITY OF GDANSK   (Poland)

ⁱ Medical University   (Poland)

^j NICOLAUS COPERNICUS UNIVERSITY   (Poland)

more..

Author keywords

Acute myeloid leukemia; Drug resistance; Drug sensitivity; Hematopoietic stem cell transplantation

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ETOPOSIDE; FLUDARABINE; MITOXANTRONE; TIOGUANINE; TREOSULFAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; BONE MARROW CELL; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG SENSITIVITY; EX VIVO STUDY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; ANTINEOPLASTIC AGENTS; BUSULFAN; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; GRANULOCYTE PRECURSOR CELLS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; LEUKEMIA, MYELOID; MALE; PROGNOSIS; RECURRENCE; TREATMENT OUTCOME; VIDARABINE;

EID: 34249298012     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Den Boer ML, Harms DO, Pieters R, Kazemier KM, Gobel U, Korholz D, Graubner U, Haas RJ, Jorch N, Spaar HJ, Kaspers GJ, Kamps WA, Van der Does-Van den Berg A, Van Wering ER, Veerman AJ and Janka-Schaub GE: Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol 21: 3262-3268, 2003.
2. Styczynski J and Wysocki M: Is the in vitro drug resistance profile the strongest prognostic factor in childhood acute lymphoblastic leukemia? J Clin Oncol 22: 963-964, 2004.
3. Zwaan CM, Kaspers GJ, Pieters R, Hahlen K, Huismans DR, Zimmermann M, Harbott J, Slater RM, Creutzig U and Veerman AJ: Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities. Blood 100: 3352-3360, 2002.
4. Yamada S, Hongo T, Okada S, Watanabe C, Fujii Y and Ohzeki T: Clinical relevance of in vitro chemoresistance in childhood acute myeloid leukemia. Leukemia 15: 1892-1897, 2001.
5. Palle J, Frost BM, Forestier E, Gustafsson G, Nygren P, Hellebostad M, Jonsson OG, Kanerva J, Schmiegelow K, Larsson R and Lonnerholm G: Cellular drug sensitivity in MLL-rearranged childhood acute leukaemia is correlated to partner genes and cell lineage. Br J Haematol 129: 189-198, 2005.
6. Klumper E, Pieters R, Kaspers GJ, Huismans DR, Loonen AH, Rottier MM, van Wering ER, van der Does-van den Berg A, Hahlen K and Creutzig U: In vitro chemosensitivity assessed with the MTT assay in childhood acute non-lymphoblastic leukemia. Leukemia 9: 1864-1869, 1995.
7. Staib P, Staltmeier E, Neurohr K, Cornely O, Reiser M and Schinkothe T: Prediction of individual response to chemotherapy in patients with acute myeloid leukaemia using the chemosensitivity index Ci. Br J Haematol 128: 783-791, 2005.
8. Miller CB, Zehnbauer BA, Piantadosi S, Rowley SD and Jones RJ: Correlation of occult clonogenic leukemia drug sensitivity with relapse after autologous bone marrow transplantation. Blood 78: 1125-1131, 1991.
9. Styczynski J and Wysocki M: Ex vivo drug resistance in childhood acute myeloid leukemia on relapse is not higher than at first diagnosis. Pediatr Blood Cancer 42: 195-199, 2004.
10. Styczynski J, Kurylak A and Wysocki M: Cytotoxicity of cortivazol in childhood acute lymphoblastic leukemia. Anticancer Res 25: 2253-2258, 2005.
11. Creutzig U, Zimmermann M, Ritter J, Reinhardt D, Hermann J, Henze G, Jurgens H, Kabisch H, Reiter A, Riehm H, Gadner H and Schellong G: Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia 19: 2030-2042, 2005.
12. Ravindranath Y, Chang M, Steuber CP, Becton D, Dahl G, Civin C, Camitta B, Carroll A, Raimondi SC and Weinstein HJ: Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. Leukemia 19: 2101-2116, 2005.
13. Ribeiro RC, Razzouk BI, Pounds S, Hijiya N, Pui CH and Rubnitz JE: Successive clinical trials for childhood acute myeloid leukemia at St Jude Children's Research Hospital, from 1980 to 2000. Leukemia 19: 2125-2129, 2005.
14. Kardos G, Zwaan CM, Kaspers GJ, de-Graaf SS, de Bont ES, Postma A, Bokkerink JP, Weening RS, van der Does-van den Berg A, van Wering ER, Korbijn C and Hahlen K: Treatment strategy and results in children treated on three Dutch Childhood Oncology Group acute myeloid leukemia trials. Leukemia 19: 2063-2071, 2005.
15. Tallman MS: New agents for the treatment of acute myeloid leukemia. Best Pract Res Clin Haematol 19: 311-320, 2006.
16. Hubeek I, Peters GJ, Broekhuizen R, Zwaan CM, Kaaijk P, van Wering ES, Gibson BE, Creutzig U, Janka-Schaub GE, den Boer ML, Pieters R and Kaspers GJ: In vitro sensitivity and cross-resistance to deoxynucleoside analogs in childhood acute leukemia. Haematologica 91: 17-23, 2006.